Evidence map›Paper›PMID 36160433›Full record

ArticleFrontiers in pharmacology2022

The cardioprotective effects and mechanisms of naringenin in myocardial ischemia based on network pharmacology and experiment verification.

Yakun Yang, Jiaying Qi, Muqing Zhang, Pingping Chen, Yanshuang Liu, Xiaorun Sun, Li Chu

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Pharmacokinetics of Dasatinib in Rats: a Potential Food-Drug Interaction with Naringenin.European journal of drug metabolism and pharmacokinetics · 2024
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yakun YangSchool of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China.
Jiaying QiSchool of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China.
Muqing ZhangCollege of Integrative Medicine, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China.
Pingping ChenCollege of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China.
Yanshuang LiuCollege of Integrative Medicine, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China.
Xiaorun SunCollege of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China.
Li ChuSchool of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Naringenin (Nar) is a natural flavonoid extracted from citrus fruits with abundant pharmacological properties against cardiac diseases, but existing studies are unsystematic and scattered. The present research systematically investigates the mechanism of action of Nar in the treatment of myocardial ischemia (MI). Network pharmacology was used to analyze the relevant targets of Nar against MI as well as the biological mechanisms. The protective effect of Nar was initially assessed in H9c2 cells induced by CoCl

Indexed as

apoptosisl-type Ca 2+ currentsmyocardial ischemianaringeninnetwork pharmacologyoxidative stress

Identifiers

PMID36160433
PMCPMC9500410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.